IP Verse

Use Of Long-Acting Glp-1 Peptides - EP3689365

The patent EP3689365 was granted to Novo Nordisk on Aug 6, 2025. The application was originally filed on Jun 21, 2013 under application number EP20157813A. The patent is currently recorded with a legal status of "Granted And Under Opposition".

EP3689365

NOVO NORDISK
Application Number
EP20157813A
Filing Date
Jun 21, 2013
Status
Granted And Under Opposition
Jul 4, 2025
Grant Date
Aug 6, 2025
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (4)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateOpposition Status

Get instant alerts for new oppositions and patent status changes

DR REDDYS LABORATORIESAug 27, 2025 -
ADALVOAug 10, 2025 -
GENERICS UKAug 7, 2025 -
WUESTHOFF & WUESTHOFFAug 6, 2025ADMISSIBLE

Patent Citations (22) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONWO03002136
DESCRIPTIONWO2005027978
DESCRIPTIONWO2005049061
DESCRIPTIONWO2006097537
DESCRIPTIONWO2008145728
DESCRIPTIONWO2009030738
DESCRIPTIONWO2009083549
DESCRIPTIONWO9319175
DESCRIPTIONWO9808871
OPPOSITIONEP3689365
OPPOSITIONWO2014005858
OTHERUS2009156478
OTHERWO03002136
OTHERWO2010092163
OTHERWO2011138421
OTHERWO2012080471
OTHERWO2012107476
OTHERWO2012177929
SEARCHWO2010092163
SEARCHWO2011138421
SEARCHWO2012107476
SEARCHWO2012177929

Non-Patent Literature (NPL) Citations (20) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
DESCRIPTION- Analytical Biochemistry, (19760000), vol. 72, pages 248 - 254-
DESCRIPTION- Analytical Biochemistry, (19960000), vol. 236, pages 302 - 308-
DESCRIPTION- HODGSON et al., "The synthesis of peptides and proteins containing non-natural amino acids", Chemical Society Reviews, (20040000), vol. 33, no. 7, pages 422 - 430, XP008067398-
DESCRIPTION- POULSENJENSEN, Journal of Biomolecular Screening, (20070000), vol. 12, pages 240 - 247-
DESCRIPTION- WILKEN et al., Diabetologia, (20000000), vol. 43, no. 51-
EXAMINATION- Anon, "Company Announcement No 40/2012 Novo Nordisk to initiate phase 3 development of semaglutide, a once-weekly GLP-1 analogue", (20120621), pages 1 - 4, URL: https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=2286, XP093133939-
EXAMINATION- Anon, "Protocol of clinical trial NCT00696657 entitled "A Randomised Controlled Clinical Trial in Type 2 Diabetes Comparing Semaglutide to Placebo and Liraglutide", v8 22.09.2011", (20110922), pages 1 - 5, URL: https://clinicaltrials.gov/study/NCT00696657?tab=history&a=8, (20230712), XP093063232-
EXAMINATION- Bhansali ET AL, "Historical Overview of Incretin Based Therapies", JAPI, (20100601), vol. 58, pages 1 - 14, XP055592040-
EXAMINATION- AHRÉN BO ET AL, "Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial", THE LANCET / DIABETES & ENDOCRINOLOGY, UK, (20170501), vol. 5, no. 5, doi:10.1016/S2213-8587(17)30092-X, ISSN 2213-8587, pages 341 - 354, XP093240282
OPPOSITION- D1_P's submission of 241112-
OTHER- Anon, "Company Announcement No 40/2012 Novo Nordisk to initiate phase 3 development of semaglutide, a once-weekly GLP-1 analogue", (20120621), pages 1 - 4, XP093133939-
OTHER- Anon, "Protocol of clinical trial NCT00696657 entitled "A Randomised Controlled Clinical Trial in Type 2 Diabetes Comparing Semaglutide to Placebo and Liraglutide", v8 22.09.2011", ClinicalTrials.gov, (20110922), pages 1 - 5, URL: https://clinicaltrials.gov/study/NCT00696657?tab=history&a=8, (20230712), XP093063232-
OTHER- Anonymous, "Safety, Tolerability, and Profile of Action of Drug in the Body of NN9535 in Healthy Male Japanese and Caucasian Subjects", ClinicalTrials.gov Identifier : NCT00851773, (20091029), pages 1 - 11, ClinicalTrials.gov Identifier : NCT00851773, URL: https://beta.clinicaltrials.gov/study/NCT00851773?tab=history, (20240108), XP093116691-
OTHER- Bhansali, Et Al., "Historical Overview of Incretin Based Therapies", JAPI, (20100601), vol. 58, pages 1 - 14, XP055592040-
OTHER- Clinicaltrials, "A Randomised Controlled Clinical Trial in Type 2 Diabetes Comparing Semaglutide to Placebo and Liraglutide", ClinicalTrials.com, (20080916), pages 1 - 36, ClinicalTrials.com, URL: https://clinicaltrials.gov/ct2/history/NCT00696657?V_8=View#StudyPageTop, (20240105), XP093116233-
OTHER- Lovshin Julie A., Daniel J. Drucker, "Incretin-Based therapies for type 2 diabetes mellitus", Nat. Rev. Endocrinol., (20090101), vol. 5, pages 262 - 269, XP093116221-
OTHER- Ahrén Bo, Masmiquel Luis, Kumar Harish, Sargin Mehmet, Karsbøl Julie Derving, Jacobsen Sanja Hald, Chow Francis, "Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial", The lancet / Diabetes & Endocrinology, UK , (20170501), vol. 5, no. 5, doi:10.1016/S2213-8587(17)30092-X, ISSN 2213-8587, pages 341 - 354, XP093240282
OTHER- S. MADSBAD, "An overview of once-weekly glucagon-like peptide-1 receptor agonists-available efficacy and safety data and perspectives for the future", Diabetes, Obesity and Metabolism, (20110105), vol. 13, doi:10.1111/j.1463-1326.2011.01357.x, pages 394 - 407, XP055043880
OTHER- Monami Matteo et al, "Effects of Glucagon-Like Peptide-1 Receptor Agonists on Body Weight: A Meta-Analysis", Experimental Diabetes Research, Hindawi Publishing Corporation, US, US , (20120101), vol. 2012, doi:10.1155/2012/672658, ISSN 1687-5214, pages 1 - 8, XP093116709
SEARCH- S. Madsbad ET AL, "An overview of once-weekly glucagon-like peptide-1 receptor agonists-available efficacy and safety data and perspectives for the future", Diabetes, Obesity and Metabolism, (20110324), vol. 13, no. 5, doi:10.1111/j.1463-1326.2011.01357.x, ISSN 1462-8902, pages 394 - 407, XP055043880 [X] 1-12 * pages 396,398,; figures 1-3 *

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents